TaiRx, Inc. (TPEX:6580)
Taiwan
· Delayed Price · Currency is TWD 29.05
+0.65 (2.29%)
Feb 21, 2025, 1:13 PM CST
TaiRx Revenue
TaiRx had revenue of 265.00K TWD in the half year ending June 30, 2024, a decrease of -57.12%. This brings the company's revenue in the last twelve months to 5.32M, down -15.98% year-over-year. In the year 2023, TaiRx had annual revenue of 5.08M, down -26.59%.
Revenue (ttm)
5.32M
Revenue Growth
-15.98%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5.08M | -1.84M | -26.59% |
| Dec 31, 2022 | 6.92M | 1.78M | 34.66% |
| Dec 31, 2021 | 5.14M | 1.78M | 53.05% |
| Dec 31, 2020 | 3.36M | 203.00K | 6.43% |
| Dec 31, 2019 | 3.16M | 1.66M | 110.26% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 8.32B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 16.71B |
| Lotus Pharmaceutical | 17.59B |
| Lumosa Therapeutics | 37.82M |
| Oneness Biotech | 112.20M |
| Polaris Group | 75.65M |
| Pegavision | 7.06B |